Invega

Paliperidone, the active ingredient in Invega, is a second‑generation atypical antipsychotic presented as an oral tablet for oral use. It is indicated for the treatment of schizophrenia and schizoaffective disorder in adult patients.

GNH USA supplies Invega as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Clients benefit from comprehensive documentation, traceability, and responsive technical support throughout the procurement process, and timely delivery.

Invega (paliperidone) is used in the management of psychotic disorders within the schizophrenia spectrum.

- Schizophrenia: reduces acute psychotic symptoms and helps prevent relapse. - Schizoaffective disorder: stabilizes mood and psychotic features. - Maintenance treatment of schizophrenia: supports long‑term symptom control after initial stabilization.

Paliperidone may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Insomnia: difficulty falling or staying asleep. - Weight gain: increase in body mass index. - Extrapyramidal symptoms: tremor, rigidity, or akathisia. - Dizziness: sensation of light‑headedness or imbalance. - Dry mouth: reduced salivation causing oral discomfort.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: life‑threatening reaction with fever and muscle rigidity. - Tardive dyskinesia: persistent involuntary movements. - Orthostatic hypotension: marked drop in blood pressure upon standing. - Seizures: occurrence of convulsive episodes, especially in predisposed patients.

When prescribing paliperidone, clinicians should consider several precautionary measures to ensure safe use.

- Dose titration: start low and adjust based on response and tolerability. - Cardiovascular monitoring: assess blood pressure and ECG for QT prolongation. - Metabolic screening: monitor weight, glucose, and lipid levels regularly. - Pregnancy and lactation: evaluate risk‑benefit; use only if clearly needed. - Drug interactions: review concomitant medications for CYP450 substrates. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture.

Paliperidone can interact with other medicines, affecting its plasma concentration or enhancing adverse effects.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): may markedly reduce paliperidone levels. - Antihypertensive agents (e.g., alpha‑blockers): additive orthostatic hypotension risk. - QT‑prolonging drugs (e.g., quinidine, haloperidol): increase risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise paliperidone exposure. - CNS depressants (e.g., benzodiazepines, opioids): may enhance sedation. - Anticholinergic agents: may worsen cognitive side effects.